Evidence map›Paper›PMID 7979302›Full record

Trial reportAntimicrobial agents and chemotherapy1994

Clinical trial of fusidic acid for lepromatous leprosy.

S G Franzblau, G P Chan, B G Garcia-Ignacio, V E Chavez, J B Livelo, C L Jimenez, M L Parrilla, R F Calvo, D L Williams, T P Gillis

Open access · greenAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Antimicrobial agents and chemotherapy, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 23 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

S G FranzblauLaboratory Research Branch, Gillis W. Long Hansen's Disease Center, Louisiana State University, Baton Rouge 70894.
G P Chan
B G Garcia-Ignacio
V E Chavez
J B Livelo
C L Jimenez
M L Parrilla
R F Calvo
D L Williams
T P Gillis
National Hansen's Disease Program · US

Funding

VACCINE DEVELOPMENT AGAINST S. JAPONICUMP50AI030601 · NIAID · RESEARCH INSTITUTE FOR TROPICAL MEDICINE · PI OLVEDA, REMIGIOM MEDINA · 1991 to 1995
–
NIAID NIH HHS AI30601
6 · The paper itself

Abstract

Fusidic acid was assessed for antileprosy activity in nine lepromatous leprosy patients. Patients received fusidic acid at either 500 mg/day for 12 weeks or 750 mg/day for 4 weeks followed by 500 mg/day for 8 weeks. All patients showed time-dependent clinical improvement and decreases in bacillary morphological index, radiorespirometric activity and PCR signal, and in serum phenolic glycolipid I. Fusidic acid appears to be a weakly bactericidal antileprosy agent which may have a role in the multidrug treatment of leprosy pending an evaluation of lepra-reaction-suppressive activity.

Indexed as

Antigens, BacterialAdolescentAdultAnimalsChildFemaleFootFusidic AcidGlycolipidsHumansLeprosy, LepromatousMaleMiceMicrobial Sensitivity TestsMycobacterium lepraePolymerase Chain ReactionAntigens, BacterialFusidic AcidGlycolipidsphenolic glycolipid I, Mycobacterium leprae

Identifiers

PMID7979302
PMCPMC284609
OpenAlexW2121952266

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.